IMARC Group’s report titled “Influenza Diagnostics Market Report by Product (Test Kit and Reagents, Instruments, and Others), Test Type (Molecular Diagnostic Tests, Traditional Diagnostic Tests), Type of Flu (Type A Flu, Type B Flu, Type C Flu), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032”. The global influenza diagnostics market size reached US$ 952.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,594.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
Grab a sample PDF of this report: https://www.imarcgroup.com/influenza-diagnostics-market/requestsample
Factors Affecting the Growth of the Influenza Diagnostics Industry:
- Increasing Incidences of Influenza:
As the incidence of influenza is rising, there is an increase in the demand for diagnostic testing. Healthcare providers need accurate and efficient diagnostic tools to confirm influenza infections promptly, enabling appropriate treatment and infection control measures. Timely diagnosis of influenza is essential for effective management and control of the disease. With increasing incidences, there is a greater emphasis on early detection to initiate appropriate treatment promptly, reduce the severity of symptoms, and prevent complications. This is driving the adoption of influenza diagnostic tests.
- Technological Advancements:
Innovations are leading to the development of diagnostic assays with improved sensitivity and specificity for detecting influenza viruses. Advanced molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) offer high sensitivity and can accurately differentiate between influenza virus strains, including seasonal and novel variants. The development of rapid influenza diagnostic tests (RIDTs) is revolutionizing point-of-care (POC) testing by providing quick results within minutes. These tests utilize innovative technologies, such as lateral flow immunoassays or molecular-based assays, to detect influenza antigens or viral RNA, enabling timely diagnosis and initiation of treatment.
- Increasing Awareness and Screening Programs:
Increasing awareness campaigns educate individuals about the signs and symptoms of influenza, encouraging them to seek medical attention promptly when experiencing flu-like symptoms. This heightened awareness leads to more frequent consultations with healthcare providers for diagnostic testing, thereby driving the demand for influenza diagnostics. Awareness initiatives emphasize the importance of early detection and treatment of influenza to prevent complications and reduce the spread of the virus.
Leading Companies Operating in the Global Influenza Diagnostics Industry:
- Abbott Laboratories
- Becton Dickinson and Company
- Coris Bioconcept
- Danaher Corporation
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd (Roche Holding AG)
- Hologic Inc.
- Meridian Bioscience Inc.
- Qiagen N.V
- Quidel Corporation
- Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
- Siemens Healthineers AG (Siemens AG)
Influenza Diagnostics Market Report Segmentation:
By Product:
- Test Kit and Reagents
- Instruments
- Others
Test kit and reagents represent the largest segment due to their necessity for conducting influenza diagnostics efficiently and accurately.
By Test Type:
- Molecular Diagnostic Tests
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Tests
- Other Molecular Tests
- Traditional Diagnostic Tests
- Rapid Influenza Diagnostic Tests
- Viral Culture Tests
- Direct Fluorescent Antibody Test
- Serological Tests
Traditional diagnostic tests account for the majority of the market share owing to their accessibility, cost-effectiveness, and established diagnostic protocols.
By Type of Flu:
- Type A Flu
- Type B Flu
- Type C Flu
Type A flu exhibits a clear dominance in the market driven by the rising demand for diagnostic testing and influencing their dominance in the market.
By End User:
- Hospitals
- Diagnostic Laboratories
- Others
Hospitals hold the biggest market share as they serve as primary points of care for patients presenting with influenza symptoms, leading to high utilization of diagnostic tests within hospital settings.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the influenza diagnostics market on account of advanced healthcare infrastructure, high awareness levels, extensive research activities, and favorable regulatory policies.
Global Influenza Diagnostics Market Trends:
There is a shift towards molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), due to their high sensitivity, specificity, and ability to detect multiple influenza strains simultaneously. The demand for rapid and convenient diagnostic solutions at the point of care (POC) is driving the adoption of POCT devices, enabling timely diagnosis, treatment decisions, and infection control measures.
Multiplex diagnostic assays capable of detecting multiple respiratory pathogens alongside influenza viruses are gaining traction, streamlining testing workflows and improving efficiency in respiratory infection management.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163